AVT03 is a proposed biosimilar candidate to Prolia and Xgeva, developed by Alvotech hf. The application was submitted by Dr Reddy’s Swiss. Shares of Dr Reddy’s Laboratories Ltd ended at ₹1,273.00, down by ₹7.20, or 0.57%, on the BSE.
AVT03 is a proposed biosimilar candidate to Prolia and Xgeva, developed by Alvotech hf. The application was submitted by Dr Reddy’s Swiss. Shares of Dr Reddy’s Laboratories Ltd ended at ₹1,273.00, down by ₹7.20, or 0.57%, on the BSE.